Finance

Lists
Why is CGEM up 4.72%?
Dive Deeper
CGEM:NASDAQ
Cullinan Therapeutics Inc
$ 11.31
+4.72%
(+0.51) 1D
$ 11.51
+1.77% (+0.20)
After hours
Closed: 11-р сарын 6, 16:00:01 (GMT-5)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEM...
Open
$ 11.09
High
$ 11.77
Low
$ 10.69
Mkt. cap
727.85 сая
Avg. vol.
926.44 мян
Volume
755.71 мян
52-wk high
$ 23.19
52-wk low
$ 6.73
EPS
-$ 3.41
Beta
-0.03
Shares outstanding
64.36 сая
No. of employees
109
Open
$ 11.09
High
$ 11.77
Low
$ 10.69
Mkt. cap
727.85 сая
Avg. vol.
926.44 мян
Volume
755.71 мян
52-wk high
$ 23.19
52-wk low
$ 6.73
EPS
-$ 3.41
Beta
-0.03
Shares outstanding
64.36 сая
No. of employees
109
News stories
From web sources and news partners
About Cullinan Therapeutics Inc
CEO-
Employees109
Founded2016
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 13 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current $ 11.31
$ 47.00 (+315.56%)
Average
$ 35.73 (+215.92%)
Lowest
$ 27.00 (+138.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Reiterated
$ 42.00
+271.4%
11/05/2026
Boris Peaker
JonesTrading
Buy
Maintained
$ 36.00
+218.3%
11/04/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
11/04/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$ 35.00
+209.5%
11/03/2026
Julian Harrison
BTIG
Buy
Maintained
$ 41.00
+262.5%
11/02/2026
Samantha Semenkow
Citi
Buy
Maintained
$ 33.00
+191.8%
10/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$ 35.00
+209.5%
10/02/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
09/24/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$ 39.00
+244.8%
09/16/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$ 30.00
+165.3%
09/15/2026
David Dai
UBS
Buy
Maintained
$ 27.00
+138.7%
08/17/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$ 28.00
+147.6%
08/13/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
$ 47.00
+315.6%
08/14/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/10/2026
Soumit Roy
JonesTrading
Buy
Maintained
$ 36.00
+218.3%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$ 30.00
+165.3%
03/10/2026
Last report
2026 оны 8-р сарын 6
Fiscal period
Q2 2026
-$ 0.81 / -$ 0.85
+4.85%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41.97 сая
42.94 сая
42.12 сая
44.44 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.63 сая
12.31 сая
11.57 сая
12.82 сая
Operating expense
55.60 сая
55.26 сая
53.70 сая
57.25 сая
Total operating expenses
55.60 сая
55.26 сая
53.70 сая
57.25 сая
Operating income
-55.60 сая
-55.26 сая
-53.70 сая
-57.25 сая
Other non operating income
-108.00 мян
-69.00 мян
-62.00 мян
-98.00 мян
EBT including unusual items
-50.61 сая
-50.71 сая
-49.66 сая
-53.70 сая
EBT excluding unusual items
-50.61 сая
-50.71 сая
-49.66 сая
-53.70 сая
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-50.61 сая
-50.71 сая
-49.66 сая
-53.70 сая
Net profit margin
-
-
-
-
Earnings per share
-0.77
-0.77
-0.75
-0.81
Interest and investment income
5.09 сая
4.62 сая
4.10 сая
3.65 сая
Interest expense
-
-
-
-
Net interest expenses
5.09 сая
4.62 сая
4.10 сая
3.65 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-55.52 сая
-55.18 сая
-53.62 сая
-57.18 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google аппс